CTOS

The GPNMB-targeted agent known as glembatumumab vedotin was reasonably well tolerated and showed some activity in a phase II study of recurrent/refractory osteosarcoma, but this activity was not enough to continue the drug’s evaluation in this setting based on the study protocol.

An analysis of more than 800 patients found that the one-size-fits-all approach to “aftercare” for localized soft-tissue sarcoma is misguided. Local recurrence and distant metastasis occur in a non-constant fashion in the years after treatment, and a time- and risk-adapted strategy for aftercare is warranted.

Treatment with hyperthermia improved survival when added to neoadjuvant chemotherapy for patients with localized high-risk soft-tissue sarcoma.